Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Mounting evidence from recent studies has revealed the association of lncRNA PANDAR expression levels with outcomes in several types of cancer. However, inconsistent results have also been reported, which rationalized a meta-analysis of available data to analyze the prognostic value of lncRNA PANDAR.
Methods: From inception to May 26, 2018, electronic literature databases including PubMed (medline), the Cochrane Library, ScienceDirect, Springer, ISI Web of Knowledge, Wiley Online library, BioMed Central, and Embase were searched for literature collections. The hazard ratios (HR) with 95% confidence interval (95% CI) were utilized to calculate pooled effect size.
Results: A total of 1,132 cancer patients were enrolled in the present meta-analysis to assess the prognostic value of PANDAR in various carcinomas. Promoted PANDAR expression was demonstrated to significantly predict unfavorable OS (HR = 1.77, 95% CI: 1.12 - 2.80, p = 0.014) by the random effects model. According to the stratified analyses and meta-regression results, the heterogeneity of present analysis may be attributed to the differences of cancer resources. Furthermore, over-expression of PANDAR was revealed to be effectively predictive of cancer progression (HR = 1.70, 95% CI: 1.41 - 2.05, p < 0.00001) and LNM (HR = 1.71, 95% CI: 1.39 - 2.10, p < 0.00001).
Conclusions: The present findings indicate that increased PANDAR is associated with poor OS in patients with general carcinomas and may serve as a useful clinical prognostic biomarker.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2018.180622 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The diagnostic and predictive value of LncRNA PANDAR in gastric cancer and its regulation of gastric cancer progression via miR-637.
Hereditas
July 2025
Department of Gastrointestinal Surgery, Huanggang Central Hospital Affiliated to Yangtze University, Dabie Mountain Regional Medical Center, No. 6, Qi'an Avenue, Huangzhou District, Huanggang, 438000, China.
Background: Gastric cancer (GC) remains a global health challenge due to its high morbidity, late-stage diagnosis, and limited therapeutic options. long non-coding RNA PANDAR has been implicated in tumorigenesis across multiple cancers, yet its role in GC pathogenesis and diagnostic utility is still unclear. The purpose of this study is to elucidate the diagnostic value of serum PANDAR and its regulatory mechanisms in GC progression.
View Article and Find Full Text PDFExpanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer.
Int Rev Cell Mol Biol
February 2025
Division of Cancer Research and Therapeutics, Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangaluru, Karnataka, India. Electronic address:
Renal cell carcinoma (RCC) and Bladder cancer (BC) are two lethal urological cancers that require diagnosis at their earliest stage causing decreasing survival rates in case of aggressive disease. However, there is no reliable circulating marker in blood or urine for their less or non-invasive diagnosis. Our objective was to review the potential circulating biomarkers, namely proteins, micro-RNA (miRNA), long non-coding RNA (lncRNA), and circulating tumour cells (CTCs) for which we performed a PubMed-based literature search of biomolecules (protein, miRNA, lncRNA and CTCs) found as circulating biomarkers in blood and urine for the early detection of RCC and BC.
View Article and Find Full Text PDFHypomethylation at PANDAR promoter progressively induces senescence in adipocyte precursor cells in subjects with obesity and type 2 diabetes.
FASEB J
October 2024
Department of Translational Medicine, Federico II University of Naples, Naples, Italy.
Article Synopsis
- * Researchers identified PANDAR, a long non-coding RNA (lncRNA), as significantly up-regulated in APCs of individuals with obesity, particularly those transitioning from normal glucose tolerance to impaired glucose tolerance or T2D.
- * Silencing PANDAR in senescent APCs appears to reverse senescence and enable cell cycle re-entry, suggesting that targeting PANDAR may offer a new approach to prevent or delay the progression toward T2D in obese patients.
Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis.
Leuk Res
December 2024
Department of Biotechnology, National Institute of Pharmaceutical Education & Research (NIPER), Ahmedabad, Palaj, Gandhinagar, Gujarat 382355, India. Electronic address:
Article Synopsis
- Long noncoding RNAs (lncRNAs) may serve as important prognostic biomarkers for acute myeloid leukaemia (AML), influencing patient outcomes significantly.
- A systematic review analyzed 27 studies involving 5,665 patients, revealing that abnormal lncRNA expression correlates with worse overall survival and lower remission rates in AML patients.
- Specific lncRNAs like HOTAIR and MALAT1 are linked to poor prognosis, while decreased expression of IRAIN is also associated with worse outcomes.
The Long Noncoding RNA PANDAR as a Prognostic and Diagnostic Biomarker in Panceratic Cancer .
Curr Cancer Drug Targets
July 2024
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Pancreatic cancer (PC) is a lethal complication in the world, affecting around half a million individuals each year. The treatment of PC is relatively difficult due to the difficulty in making an early diagnosis. Most PC patients are confronted with locally metastatic or advanced diseases in the asymptomatic phase, and about 80% have late diagnosis with metastasis.
View Article and Find Full Text PDF